source
- Alnylam’s heart drug outlook dimmed as rival eplontersen fails at ESC CongressThe European Society of Cardiology Congress in Munich is a focal point for Alnylam Pharmaceuticals as it seeks clarity on the future of its two ATTR-CM programs. Data presented by AstraZeneca and…
- FDA approves Roivant's brepocitinib for rare autoimmune disease dermatomyositisOn Thursday the U.S. Food and Drug Administration gave its nod to a new therapy from Roivant Sciences and its subsidiary Priovant. The oral medication, brepocitinib, will be sold under the brand na…